Journal of Pharmacogenomics and Pharmacoproteomics最新文献

{"title":"Adjunctive Treatment Considerations for the Addressment of Inflammation in Neuromuscular Disorders","authors":"R. Panganiban","doi":"10.4172/2153-0645.1000169","DOIUrl":"https://doi.org/10.4172/2153-0645.1000169","url":null,"abstract":"Objective: To explore the use of IGF-1 platelet rich plasma/adipocyte mesenchymal stem cells to address inflammation in its role seen in neuromuscular disorders. Methods: IGF-1 applications in the clinical setting. Platelet rich plasma/adipocyte mesenchymal stem cell harvesting techniques. Main outcome measurements: Functional improvement with basic and advanced activities of daily living and improved management of Pain. Conclusion: IGF-1/adipocyte mesenchymal stem cell/PRP as possible adjunctive treatment options exist in the addressment of inflammation seen in neuromuscular disorders.","PeriodicalId":333396,"journal":{"name":"Journal of Pharmacogenomics and Pharmacoproteomics","volume":"84 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131912726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WaterMap originates in dehydron-based drug design","authors":"Ariel Fernández","doi":"10.4172/2153-0645.100E156","DOIUrl":"https://doi.org/10.4172/2153-0645.100E156","url":null,"abstract":"Copyright: © 2017 Fernández A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Drug-based targeted therapy demands skillful and subtle molecular design. The ease with which water may be locally removed from around the target protein provides a striking blueprint that steers the design process. To that effect, local de-wetting propensities have been mapped on the aqueous interface of the target proteins. These maps have served as precursors to WaterMap, now the gold standard in the field.","PeriodicalId":333396,"journal":{"name":"Journal of Pharmacogenomics and Pharmacoproteomics","volume":"66 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126195939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Cholesteryl Ester Transfer Protein (CETP) Taqib and I405V Gene Polymorphisms and Statin Treatment","authors":"Bousoula Eleni, Kolovou Vana, Boutsikou Maria, Tapola Anastasia, Perrea Despoina, Kolovou Genovefa","doi":"10.4172/2153-0645.1000168","DOIUrl":"https://doi.org/10.4172/2153-0645.1000168","url":null,"abstract":"Background: CETP (cholesterol ester transfer protein) is a plasma protein that facilitates the transport of cholesteryl esters and triglycerides between the lipoproteins. It is composed mainly at the liver and it collects triglycerides from chylomicrons and VLDL and exchanges them for cholesteryl esters from HDL. By this mean, very dense LDL molecules are being formed. The latter are very atherogenetic factors. The gene encoding CETP is located on the long (q) arm of chromosome 16 at position 21. It has been found that at least two polymorphisms in this gene, TaqIB (with B1B1, B1B2 and B2B2 genotypes) and I405V (with II, IV and VV genotypes), have been associated with different response to statin treatment. Aim: The aim of this study was to investigate a probable correlation of the aforementioned CETP gene polymorphisms with better or worse response to two specific statins: simvastatin and atorvastatin. Methods: The DNA of 78 subjects, 53 men (67.9%) and 25 women (32.1%) of mean age 57±20 years with dyslipidemia, was analyzed for the different genotypes of the CETP gene polymorphisms TaqIB and I405V. To all these patients simvastatin and atorvastatin were administered as lipid lower agents and they had a lipid profil test four times during the study period. Namely, before the beginning of the therapy, two months after taking the first statin (either simvastatin or atorvastatin), two months after they quitted therapy and last time two months after restarting the lipid lower therapy with the other statin. Results: Both statins administered to patients succeeded to reduce significantly total cholesterol, triglycerides and LDL-C levels and simultaneously to augment significantly HDL-C levels. These changes have been observed in all patients independently of their genotype of the two studied CETP gene polymorphisms. No significant differences were demonstrated in total cholesterol, triglycerides, HDL-C and LDL-C levels before and after simvastatin and atorvastatin therapy across Taq1B and I405V genotypes. Moreover, the effect of age and gender on lipid levels, independently of which statin was used or the genotype, was not significant. Conclusion: The initial hypothesis of our study, that there is a probable correlation between different genotypes of TaqIB and I405V CETP gene polymorphisms and response to treatment with simvastatin and atorvastatin was not confirmed.","PeriodicalId":333396,"journal":{"name":"Journal of Pharmacogenomics and Pharmacoproteomics","volume":"95 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131734898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interleukin-28B Polymorphism is a Pharmacogenetic Predictor during Sofosbuvir Plus Pegylated Interferon and Ribavirin Therapy for Chronic Hepatitis C Egyptian Patients","authors":"Hosni Dh Abd EL-Raheem, M. Hashem, A. Hemeida, Mohamed E Ebeed, U. Arafa, L. Yousef","doi":"10.4172/2153-0645.1000166","DOIUrl":"https://doi.org/10.4172/2153-0645.1000166","url":null,"abstract":"Background and Aim: Interleukin-28B (IL-28B) polymorphism is a predictor of sustained virologic response (SVR), spontaneous clearance and personalizing therapy of hepatitis C virus (HCV). This study aimed to determine IL28B rs12979860 polymorphism among chronic hepatitis C (CHC) Egyptian patients as a step in personalized HCV therapy and pharmacogenomics. Methods: CHC Egyptian patients were received sofosbuvir (SOF) plus pegylated interferon (PEG-IFN) and ribavirin (RBV) for 12 weeks. A total of 82 HCV infected Egyptian patients and 27 healthy individuals were included in the present study. CHC Patients were classified as achieving SVR if plasma HCV-RNA was undetectable (group A) and non-responders if plasma HCV-RNA was detectable (group B). IL28B genotypes were analyzed and their associations with SVR were selected. Results: The end of treatment response (ETR) rate was 100%. However, SVR12 was 76.8% (group A) and 23.2% relapsed (group B). Among studied CHC patients, 50% were IL-28B TT, 40.2% CT, and 9.8% CC. while the percentage of their frequencies in the healthy persons were 18.5%, 51.8%, and 29.6%, respectively. These results showed that the frequencies of TT genotypes were more prevalent in HCV patients. The genotype CC (n=8) achieved higher rates of SVR in group A (87.5%) than relapsed patients in group B (12.5%) and it had the least prevalence in group B compared with the frequencies of CT (21.2%) and TT (26.9%) genotypes. These results showed that CC genotype was associated with SVR. Conclusions: It can be concluded that the individuals with IL28B TT genotype are more susceptible to HCV infection in Egyptian patients and relapse. Moreover, IL-28B CC is useful for pretreatment prediction of the outcome of HCV treatment. Hence, IL28B polymorphism could be considered as a pharmacogenetic predictor in personalized HCV therapy and pharmacogenomics during SOF plus PEG-IFN and RBV therapy for chronic hepatitis C Egyptian patients.","PeriodicalId":333396,"journal":{"name":"Journal of Pharmacogenomics and Pharmacoproteomics","volume":"71 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129635991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thiopurine Methyltransferase Genotype Testing in Paediatric Patients in South Australia. A Retrospective Audit into Prescribing Practices.","authors":"S. Mahindroo, J. Fletcher, P. Hissaria, P. Hakendorf, S. Nicholson","doi":"10.4172/2153-0645.1000167","DOIUrl":"https://doi.org/10.4172/2153-0645.1000167","url":null,"abstract":"Background: Thiopurines are used to treat a number of medical conditions including inflammatory bowel disease, acute lymphoblastic leukemia and severe eczema in children. Pre prescription identification of variant alleles helps reduce thiopurine related adverse events. The aim of the study was to explore the clinical utility of TPMT genotyping in a paediatric population in South Australia, specifically the uptake of testing and whether the results are guiding appropriate dosing of thiopurines in keeping with current established international guidelines. Methods: A retrospective audit was conducted reviewing all patients below the age of 18 years who underwent TPMT genotyping in South Australia during the 10-year period between January 2004 and January 2014. Data regarding demographics and prescribing practices was collected from the medical records of 260 paediatric patients. Results: Paediatric gastroenterologists requested 67% of the TPMT genotypes performed. Loss of function alleles were confirmed in almost 9% of cases. There were positive correlations between adverse events and whether the test was used correctly (p 0.011) and with subspecialty unit (p<0.001). Oncology recorded the largest percentage of adverse events 63.5% whilst only comprising 16.5% of the total dataset. Conclusion: The safest prescribing practice in all groups of patients is to ensure the TPMT gentyope is performed prior to administration and dosing is guided by the results and established guidelines.","PeriodicalId":333396,"journal":{"name":"Journal of Pharmacogenomics and Pharmacoproteomics","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131271845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined DPD and UGT1A1 Mutation in a Single Patient: A Case Report","authors":"L. P. Bhanu, S. Bj, M. Nasiruddin, N. Radheshyam","doi":"10.4172/2153-0645.1000165","DOIUrl":"https://doi.org/10.4172/2153-0645.1000165","url":null,"abstract":"Pharmacogenetic studies on 5-FU have mostly focused on enzyme Dihydropyrimidine Dehydrogenase (DPD), which is a rate-limiting enzyme in uracil and thymine catabolic pathway. Its activity has been found to be highly variable in different populations and several DPYD polymorphisms have been reported to be responsible for the decrease in activity of enzyme function and a high risk of 5-FU toxicity. Studies on 5-FU have mostly focused on t UGT1A1 genetic variations have been extensively investigated in relation to hyperbilirubinemia syndromes, as the UGT1A1 enzyme catalyses bilirubin glucuronidation. The importance of glucuronidation pathway in irinotecan treatment, UGT1A1 was chosen as the candidate gene to be investigated as a predictor of severe toxicity. Existence of combined mutation of DPD and UGT1A1 is adversely increases the treatment toxicity. A 57 year old male patient was diagnosed moderately differentiated adenocarcinoma rectum and patient was evaluated with DPD gene mutation and found positive for Heterozygous (496A19), Homozygous (855/C) and Heterozygous (1627). Thereafter, the treatment regimen was changed to IROX, patient’s conditions worsen progressively with Grade IV neutropenia and further complicated by sepsis. Patient was evaluated for UGT1A1 gene mutation. Subsequently, UGT1A1*1 and UGT1A1*28 gene was found to be mutated (Heterozygous). UGT1A1","PeriodicalId":333396,"journal":{"name":"Journal of Pharmacogenomics and Pharmacoproteomics","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129822773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The pharmacogenomic era in Asia: Potential roles and challenges for Asian pharmacists","authors":"Yin-Fai Lee, Ritchie Ching Chi Kwok, IanC K Wong, V. W. Lui","doi":"10.4172/2153-0645.1000164","DOIUrl":"https://doi.org/10.4172/2153-0645.1000164","url":null,"abstract":"Personalized medicine through Pharmacogenomics: choosing the right drug, and the right dose, for the right patients based on patient’s genetic makeup-is gradually being realised in Western countries. Yet, the practice of pharmacogenomics in Asian countries lags behind that of the West, but the medical needs for pharmacogenomics are expected to surge as better patient care is demanded in Asia. As next-generation sequencing technology advances quickly, previous technical challenges for performing pharmacogenomic studies or practices in Asia have been mostly resolved. What is lacking in Asia is an effective model of community-wide pharmacogenomics. On the delivery front, pharmacists, the drug and dosing professionals, can potentially be the main healthcare providers for pharmacogenomic services in Asia. The first large “Genomics for Precision Drug Therapy in the Community Pharmacy” in Canada, which is close to its completion, has successfully identified community pharmacists as key contact professionals for smooth facilitation and implementation of pharmacogenomics for personalized medication. It is anticipated that Asian pharmacists, with appropriate training, can have the capacity to provide expert pharmacogenomic supports for both physicians and patients in Asia.","PeriodicalId":333396,"journal":{"name":"Journal of Pharmacogenomics and Pharmacoproteomics","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134227147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Profiles of Liver Function Tests among Type 2 Diabetic Patients Who are Receiving Different Anti-Diabetic Drugs Attending Tikur Anbessa Specialized Hospitals","authors":"Desaleng Dango, M. Umeta, S. Genet, M. Menon, T. Kebede, Jemal Beker","doi":"10.4172/2153-0645.1000163","DOIUrl":"https://doi.org/10.4172/2153-0645.1000163","url":null,"abstract":"Early years of life are very important for future development and sustainable society. Things that happen during early period may effect lifetime. Children, who start life with proper food, love and care, safe nurturing environment and responsive caregivers reach their optimum development. Therefor there is call to action for early child development through implement the sustainable development goals for better future of children and communities.","PeriodicalId":333396,"journal":{"name":"Journal of Pharmacogenomics and Pharmacoproteomics","volume":"50 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133626714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allograft Tissue Implantation and Inflammatory-Immune Model Considerations for the Treatment of Osteoarthritis","authors":"R. Panganiban","doi":"10.4172/2153-0645.1000162","DOIUrl":"https://doi.org/10.4172/2153-0645.1000162","url":null,"abstract":"Coincidentally, the effects upon the immune system by inflammation have rendered inflammatory-immune considerations in the treatment of degenerative joint disease as a result. Setting: Clinical practice. Methods: Total of 77 subjects. 18 males/24 females were randomized for amniotic allograft tissue implantation with the remainder receiving corticosteroid injection (40 mg Kenalog). Serum blood work was obtained randomly (13 of the 42 total allograft tissue implantation treatment population). Results: Reduction of pain greater than 30% translating to functional improvement manifested in significant improvement in SF-36 results (Role-Physical and Bodily-Pain domains) was seen in the allograft tissue implantation population (shoulder/knee/hip joint patient population) at three months with the majority extending to six months. These results were not seen in the repeat corticosteroid population. In the glenohumeral joint population, (15/17) receiving allograft tissue implantation reported statistically significant improvement in SF-36 results (Role-Physical and Bodily-Pain domains) and (14/17) reported improved active range of motion with reduction of pain versus (2/10) receiving repeat corticosteroid injection reporting these subjective/objective findings at the three month interval. This benefit was sustained in (10/14) at six months. In the patellofemoral segment, (15/16) test patients reported benefit in the same SF-36 domains coupled with improved active functional range of motion and reduction of pain as compared to (8/20) in the repeat corticosteroid population at three months. At six months, benefit was retained in the allograft tissue population (12/16) versus (2/20) in the repeat corticosteroid population. In the femoroacetabular joint test population, (8/9) reported SF-36 improvement in the corresponding domains coupled with improved active joint range of motion and reduction of pain of at least 30%. (1/5) in the corticosteroid administration subjects reported the same benefit at three months. (8/9) allograft treated subjects preserved benefit at six months with (0/5) corticosteroid patients demonstrated benefit. Conclusion: As part of targeted multimodal treatment considerations, neuropeptide and amniotic allograft tissue may play an adjuvant role in degenerative joint disease addressment via purported inflammatory-immune pathways.","PeriodicalId":333396,"journal":{"name":"Journal of Pharmacogenomics and Pharmacoproteomics","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126361016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"E-PodoFavalin-15999 (Atremorine®): A new modality of nutrigenomic intervention in Parkinsons disease","authors":"Ramon Cacabelos Juan C Carril Oscar Teijido Lucia Fern, ezNovoa, Iván Carrera","doi":"10.4172/2153-0645.C1.009","DOIUrl":"https://doi.org/10.4172/2153-0645.C1.009","url":null,"abstract":"","PeriodicalId":333396,"journal":{"name":"Journal of Pharmacogenomics and Pharmacoproteomics","volume":"102 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115632478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}